(Q38022190)

27 August 2017

title

Current advantages in the application of proteomics in inflammatory bowel disease (English)

1 reference

inflammatory bowel diseases

27 August 2017

main subject

0 references

author name string

Anna Vaiopoulou

1

1 reference

27 August 2017

Maria Gazouli

2

1 reference

27 August 2017

George Theodoropoulos

3

1 reference

27 August 2017

George Zografos

4

1 reference

27 August 2017

language of work or name

1 reference

28 June 2012

1 reference

Digestive Diseases and Sciences

27 August 2017

published in

1 reference

27 August 2017

volume

57

1 reference

27 August 2017

issue

11

1 reference

27 August 2017

page(s)

2755-2764

1 reference

https://scigraph.springernature.com/pub.10.1007/s10620-012-2291-4

27 August 2017

exact match

0 references

cites work

Inflammatory Bowel Disease

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2291-4

Genetics and pathogenesis of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2291-4

Commensal flora: wolf in sheep's clothing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2291-4

Progress in basic inflammatory bowel disease research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2291-4

Biomarker discovery for inflammatory bowel disease, using proteomic serum profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2291-4

Biological markers in inflammatory bowel disease: practical consideration for clinicians.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2291-4

Biomarkers in inflammatory bowel disease: current practices and recent advances

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2291-4

New serological biomarkers of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2291-4

Applications of proteomics in the study of inflammatory bowel diseases: Current status and future directions with available technologies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2291-4

Blood-based proteomics for personalized medicine: examples from neurodegenerative disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2291-4

Biomarkers: mining the biofluid proteome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2291-4

Reverse-phase protein microarrays: application to biomarker discovery and translational medicine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2291-4

Applications of proteomics to lab diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2291-4

The biological impact of mass-spectrometry-based proteomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2291-4

Mining the plasma proteome for cancer biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2291-4

Modificomics: posttranslational modifications beyond protein phosphorylation and glycosylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2291-4

Protein posttranslational modifications: the chemistry of proteome diversifications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2291-4

Proteomics and chronic inflammatory bowel diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2291-4

Proteomics for the early detection and treatment of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2291-4

Analysis of proteins and proteomes by mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2291-4

Protein profiles of peripheral blood mononuclear cells are useful for differential diagnosis of ulcerative colitis and Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2291-4

Potential urinary biomarkers of disease activity in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2291-4

Proteomics for prediction and characterization of response to infliximab in Crohn's disease: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2291-4

Serum protein profiling in patients with inflammatory bowel diseases using selective solid-phase bulk extraction, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and chemometric data analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2291-4

Advances in functional protein microarray technology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2291-4

Protein microarray technology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2291-4

Identification of novel serological biomarkers for inflammatory bowel disease using Escherichia coli proteome chip

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2291-4

Protein microarray analysis of disease activity in pediatric inflammatory bowel disease demonstrates elevated serum PLGF, IL-7, TGF-beta1, and IL-12p40 levels in Crohn's disease and ulcerative colitis patients in remission versus active disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2291-4

Peptidomics technologies for human body fluids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2291-4

Proteomic technologies for the identification of disease biomarkers in serum: advances and challenges ahead

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2291-4

New serologic markers for inflammatory bowel disease diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2291-4

Human body fluid proteome analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2291-4

Clinical proteomics: Written in blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2291-4

Serum and plasma proteomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2291-4

Advances, challenges, and limitations in serum-proteome-based cancer diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2291-4

Serologic markers in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2291-4

Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2291-4

Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2291-4

New serological markers in inflammatory bowel disease are associated with complicated disease behaviour

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2291-4

Detection of antisynthetic mannoside antibodies (ASigmaMA) reveals heterogeneity in the ASCA response of Crohn's disease patients and contributes to differential diagnosis, stratification, and prediction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2291-4

Autoantibodies against ubiquitination factor E4A (UBE4A) are associated with severity of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2291-4

C-reactive protein as a marker for inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2291-4

Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2291-4

Predictors of acute relapse of Crohn's disease. A laboratory and clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2291-4

Assessment of appropriate laboratory measurements to supplement the Crohn's disease activity index

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2291-4

Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases. I. Immunology and therapeutic potential of antiadhesion molecule therapy in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2291-4

Soluble selectins, sICAM, sVCAM, and angiogenic proteins in different activity groups of patients with inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2291-4

Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2291-4

Soluble interleukin-2 receptor in Crohn's disease: relation of serum concentrations to disease activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2291-4

Soluble interleukin-2 receptors in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2291-4

Profile of soluble cytokine receptors in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2291-4

Serum interleukin-8 in inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2291-4

Circulating antiinflammatory cytokine IL-10 in patients with inflammatory bowel disease (IBD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2291-4

Enzymes in feces: useful markers of chronic inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2291-4

Review article: faecal markers in the assessment of activity in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2291-4

111Indium autologous granulocytes in the detection of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2291-4

Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2291-4

Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2291-4

Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2291-4

Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2291-4

Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2291-4

A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2291-4

Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2291-4

Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2291-4

Genetic testing in Crohn disease: utility in individualizing patient management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2291-4

Biomarkers in inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2291-4

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2291-4

Response to infliximab treatment in Crohn's disease is not associated with mutations in the CARD15 (NOD2) gene: an analysis in 534 patients from two multicenter, prospective GCP-level trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2291-4

A label-free nano-liquid chromatography-mass spectrometry approach for quantitative serum peptidomics in Crohn's disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2291-4

[Proteomics and peptidomics in fundamental and applied medical studies]

21 January 2018

1 reference

12 December 2020

Apolipoprotein A-IV Is an Independent Predictor of Disease Activity in Patients with Inflammatory Bowel Disease

1 reference

12 December 2020

Proteomics and the analysis of proteomic data: an overview of current protein-profiling technologies

1 reference

12 December 2020

Non-invasive investigation of inflammatory bowel disease

1 reference

12 December 2020

Protein arrays: a versatile toolbox for target identification and monitoring of patient immune responses

1 reference

12 December 2020

Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal inflammation

1 reference

12 December 2020

Serum orosomucoid in ulcerative colitis: its relation to clinical activity, protein loss, and turnover of albumin and IgG

1 reference

12 December 2020

Erythrocyte sedimentation as a measure of Crohn's disease activity: opposite trends in ileitis versus colitis.

1 reference

12 December 2020

Interleukin-1 receptor antagonist in differential diagnosis of inflammatory bowel diseases

1 reference

12 December 2020

Fecal lactoferrin is a sensitive and specific marker of disease activity in children and young adults with inflammatory bowel disease

1 reference

12 December 2020

CXCL16 is a surrogate marker of inflammatory bowel disease

1 reference

12 December 2020

The clinical significance of serum C reactive protein levels in Crohn's disease. Results of a prospective longitudinal study

1 reference

12 December 2020

Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease

1 reference

12 December 2020

Erythrocytic sedimentation rate as a measure of clinical activity in inflammatory bowel disease

1 reference

12 December 2020

Resistin is an inflammatory marker of inflammatory bowel disease in humans

1 reference

12 December 2020

Mouse models of inflammatory bowel disease

1 reference

12 December 2020

Faecal calprotectin: a marker of inflammation throughout the intestinal tract

1 reference

12 December 2020

Optimized normalization for antibody microarrays and application to serum-protein profiling

1 reference

12 December 2020

10.1007/S10620-012-2291-4

Identifiers

DOI

1 reference

Dimensions Publication ID

27 August 2017

1033580098

0 references

Fatcat ID

release_bffy4hmd75bcpdgpj6shfo4mse

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/bffy4hmd75bcpdgpj6shfo4mse

24 November 2022

mapped directly with Wikidata item

1 reference